Highlights

  • Third quarter 2026 revenues were $173.7 million, compared with $147.1 million, and Net Income was $30.9 million.
  • Revenues before reimbursements for the quarter were $153.1 million, compared with $137.1 million a year earlier.
  • Exponent repurchased $146,138,000 of common stock in the first nine months of 2026, compared with $72,712,000.
  • Management expects 2026 net Revenue growth of 10% to 11% and EBITDA of 28% to 28.3% of net revenues.

Exponent, Inc. (NASDAQ:EXPO) shares were trading at USD 90.35 on November 20, 2026, up 1.52%, with a relative Volume at time of 2.60. The engineering and scientific consulting firm filed its report for the quarter ended October 2, 2026 on November 6, and its board announced a Cash Dividend on October 29, 2026.

Exponent is a Delaware corporation with principal executive offices at 149 Commonwealth Drive in Menlo Park, California. It is an engineering and scientific consulting firm that draws from more than 90 technical disciplines to solve complex problems and analyzes accidents and failures for clients. The company reports two segments, Engineering and Other Scientific, and Environmental and Health. Its fiscal year ended January 2, 2026, and its 2026 third quarter ended October 2, 2026.

Third Quarter 2026 Results

For the three months ended October 2, 2026, revenues were $173.7 million, compared with $147.1 million a year earlier. The company said revenues increased 18%. Revenues before reimbursements were $153.1 million, compared with $137.1 million, an increase of 12% as stated by the company.

Operating income was $41.9 million, compared with $29.0 million. Net income was $30.9 million, compared with $28.0 million. Basic and Diluted Earnings per Share were both $0.64, compared with $0.55. Diluted weighted average shares were 48.4 million, compared with 51.2 million. Comprehensive income was $30.8 million, compared with $28.1 million. Compensation and related expenses were $90.0 million, compared with $87.7 million.

Nine-Month Results and Segments

For the nine months ended October 2, 2026, revenues were $511.6 million, compared with $434.6 million, and revenues before reimbursements were $453.7 million, compared with $407.4 million. Operating Income was $111.3 million, compared with $90.6 million. Net income was $89.9 million, compared with $81.2 million, and diluted earnings per share were $1.83, compared with $1.58.

In the Engineering and Other Scientific segment, billable hours increased 10% to 334,000 in the third quarter, compared with 305,000 a year earlier, and utilization was 79%, compared with 76%. In the Environmental and Health segment, billable hours were 71,000 in the third quarter of both 2026 and 2025, and utilization was 67%, compared with 68%.

Balance Sheet, Cash Flow and Capital Returns

Cash and cash equivalents were $114.7 million at October 2, 2026, compared with $221.9 million at the start of the year. Total Assets were $694.9 million, compared with $777.5 million. Total liabilities were $387.0 million, compared with $387.2 million, and total stockholders' Equity was $307.9 million, compared with $390.3 million.

Net cash provided by Operating Activities for the nine months was $93.1 million, compared with $76.1 million. The net change in cash and cash equivalents was a decrease of $107.2 million, compared with a decrease of $51.5 million. During the first nine months of 2026, the company repurchased $146,138,000 of its common stock, compared with $72,712,000 in the same period last year.

On October 29, 2026, the Board of Directors announced a cash dividend of $0.31 per share, payable December 18, 2026, to registered stockholders as of December 4, 2026.

Outlook Discussed on the October 30 Call

On the October 30, 2026 call, management said that for the fourth quarter of 2026, compared with a year earlier, it expects net revenues to grow 8% to 10% and EBITDA to be 26.3% to 26.8% of net revenues. For the full year of 2026, management said it is raising its net revenue and Margin guidance and now expects net revenue growth of 10% to 11% and EBITDA of 28% to 28.3% of net revenues, compared with 27.6% in 2025.

Management expects fourth quarter utilization of 69% to 70% and full year utilization of 73.5% to 74%, compared with 72.5% in 2025. It expects a fourth quarter tax rate of approximately 28% and a full year tax rate of 28.5%, and capital expenditures for the full year of $10 million to $12 million.